Abstract
Glial cells are integrated part of neurovascular unit of blood brain barrier (BBB). They undergo mitosis and mainly classified as astrocytes, oligodendrocytes, microglia, ependymal cells and nerve glial antigen 2 cells. Being a most versatile glial cell, astrocytes provide structural support to neurons, maintain brain homeostasis, take part in neuronal communication, and perform some housekeeping functions. Oligodendrocytes myelinate the neuronal axons for proper transmission of nerve impulse and microglia are brain immune cells. Multiple sclerosis is a prototype glia mediated disease that manifests demyelination. Fingolimod is already being marketed for this disease, while guanabenz and ibudilast are facing clinical trials. Many researches revealed the role of glial cells in Alzheimer’s disease, in which riluzole (a glutamate modulator already in market for amyotrophic lateral sclerosis-ALS) was found to be effective. Q-cells® are glial cell-based therapeutic agent to treat ALS that only produce astrocytes and oligodendrocytes, when transplanted in vivo. hIL13-PE is a gene based therapeutic agent that has been smartly designed for the treatment of glioma. Although for CNS diseases, drugs are available, still it is not easy to extract satisfactory therapeutic effect of most of the drugs due to the presence of BBB. This barrier can be overcome by implanting a drug reservoir in brain parenchyma (wafer), by judicious selection of drug delivery system (nanoparticulate system), or by using an alternative route of administration (intranasal route). This review revolves around cellular and drug based modulation of glial cells to achieve maximum therapeutic benefit for some of the CNS diseases.
Keywords: Central nervous system, glial cells, blood-brain barrier, multiple sclerosis, cancer, pharmacotherapy, gene therapy, nanotechnology.
Current Pharmaceutical Design
Title:Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases
Volume: 23 Issue: 16
Author(s): Shakeeb Ahmed, Azka Gull, Tahir Khuroo, Mohd. Aqil and Yasmin Sultana*
Affiliation:
- Department of Pharmaceutics, Faculty of Pharmacy, Hamdard University, New Delhi,India
Keywords: Central nervous system, glial cells, blood-brain barrier, multiple sclerosis, cancer, pharmacotherapy, gene therapy, nanotechnology.
Abstract: Glial cells are integrated part of neurovascular unit of blood brain barrier (BBB). They undergo mitosis and mainly classified as astrocytes, oligodendrocytes, microglia, ependymal cells and nerve glial antigen 2 cells. Being a most versatile glial cell, astrocytes provide structural support to neurons, maintain brain homeostasis, take part in neuronal communication, and perform some housekeeping functions. Oligodendrocytes myelinate the neuronal axons for proper transmission of nerve impulse and microglia are brain immune cells. Multiple sclerosis is a prototype glia mediated disease that manifests demyelination. Fingolimod is already being marketed for this disease, while guanabenz and ibudilast are facing clinical trials. Many researches revealed the role of glial cells in Alzheimer’s disease, in which riluzole (a glutamate modulator already in market for amyotrophic lateral sclerosis-ALS) was found to be effective. Q-cells® are glial cell-based therapeutic agent to treat ALS that only produce astrocytes and oligodendrocytes, when transplanted in vivo. hIL13-PE is a gene based therapeutic agent that has been smartly designed for the treatment of glioma. Although for CNS diseases, drugs are available, still it is not easy to extract satisfactory therapeutic effect of most of the drugs due to the presence of BBB. This barrier can be overcome by implanting a drug reservoir in brain parenchyma (wafer), by judicious selection of drug delivery system (nanoparticulate system), or by using an alternative route of administration (intranasal route). This review revolves around cellular and drug based modulation of glial cells to achieve maximum therapeutic benefit for some of the CNS diseases.
Export Options
About this article
Cite this article as:
Ahmed Shakeeb, Gull Azka, Khuroo Tahir , Aqil Mohd. and Sultana Yasmin *, Glial Cell: A Potential Target for Cellular and Drug Based Therapy in Various CNS Diseases, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170316124500
DOI https://dx.doi.org/10.2174/1381612823666170316124500 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Transient Receptor Potential Vanilloid-2 Channel Expression and Function in Tumor Growth and Progression
Current Protein & Peptide Science Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology Possible Binding Mode Analysis of Pyrazolo-triazole Hybrids as Potential Anticancer Agents through Validated Molecular Docking and 3D-QSAR Modeling Approaches
Letters in Drug Design & Discovery Recognition Sites for Cancer-targeting Drug Delivery Systems
Current Drug Metabolism Natural Products as a Promising Therapeutic Strategy to Target Cancer Stem Cells
Current Medicinal Chemistry Nucleic Acid-based Technologies in Therapy of Malignant Gliomas
Current Pharmaceutical Biotechnology Harnessing Phage Display for the Discovery of Peptide-Based Drugs and Monoclonal Antibodies
Current Medicinal Chemistry Computer Modeling of Brain Tumor Growth
Mini-Reviews in Medicinal Chemistry Cell Bystander Effect Induced by Radiofrequency Electromagnetic Fields and Magnetic Nanoparticles
Current Nanoscience The Role of CXCR3 in Neurological Diseases
Current Neuropharmacology Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Neuroblastoma and Stem Cell Therapy: An Updated Review
CNS & Neurological Disorders - Drug Targets Angiogenesis-Related Cytokines in Rheumatoid Arthritis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Deglucohellebrin: A Potent Agent for Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Elucidation of Abnormal Extracellular Regulated Kinase (ERK) Signaling and Associations with Syndromic and Non-syndromic Autism
Current Drug Targets Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture